Drug Profile
FCC 13
Alternative Names: 2-N-carboxamidonormianserinLatest Information Update: 30 May 2001
Price :
$50
*
At a glance
- Originator Monash University
- Class Antiasthmatics; Dibenzazepines
- Mechanism of Action Histamine H1 receptor antagonists; Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 01 May 1995 New profile
- 01 May 1995 No-Development-Reported for Asthma in Australia (Unknown route)